Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 4/20 | 0.84 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.66 |
| ▸ | XIAP | P98170 | 12/20 | 0.54 |
| ▸ | NPY1R | P25929 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7785968 | 1.00 | GHSR (0.84) | GHSRAGTR1XIAPNPY1R | |
| SCHEMBL7785910 | 0.93 | GHSR (0.84) | GHSRAGTR1XIAPNPY1R | |
| SCHEMBL7794454 | 0.93 | GHSR (0.85) | GHSRAGTR1XIAPNPY1R | |
| SCHEMBL9024983 | 0.92 | GHSR (0.72) | GHSRAGTR1XIAPNPY1R | |
| SCHEMBL7791646 | 0.92 | GHSR (0.72) | GHSRAGTR1XIAPNPY1R | |
| SCHEMBL7438263 | 0.92 | GHSR (1.00) | GHSRAGTR1XIAPNPY1R | |
| SCHEMBL7786019 | 0.91 | GHSR (0.80) | GHSRAGTR1XIAPNPY1R | |
| SCHEMBL7791981 | 0.91 | GHSR (0.71) | GHSRAGTR1XIAPNPY1R | |
| SCHEMBL7791707 | 0.91 | GHSR (0.70) | GHSRAGTR1XIAPNPY1R | |
| SCHEMBL9024490 | 0.90 | GHSR (0.69) | GHSRAGTR1XIAPNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260077018-A1 | TREATMENT OF MILD TRAUMATIC BRAIN INJURY | OXEIA BIOPHARMACEUTICALS INC (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4583902-A2 | TREATMENT OF MILD TRAUMATIC BRAIN INJURY | Oxeia Biopharmaceuticals, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024054875-A2 | TREATMENT OF MILD TRAUMATIC BRAIN INJURY | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| US-20230330187-A1 | USE OF GHRELIN OR GHRELIN VARIANT FOR INCREASING DOSE INTENSITY OF CHEMOTHERAPEUTIC AGENTS IN PATIENTS WITH CANCER | OXEIA BIOPHARMACEUTICALS INC (US) | 2023-10-19 | — | — | US | disclosed |
| WO-2022226116-A1 | GHRELIN TREATMENT OF BRAIN DYSFUNCTION DUE TO VIRAL INFECTION | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2022-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260077018-A1 | TREATMENT OF MILD TRAUMATIC BRAIN INJURY | CRH, MYO1G, GHRHR | GHSR 6/4885AGTR1 4140/4885XIAP 2581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.